Regeneron Pharmaceuticals EBIT

The latest EBIT for 0R2M.L is $4.5B as of June 2026. That compares with $4B in the prior-year period — up 10.9% year over year. That is below the Healthcare sector average of $1.9T. Investors often review this figure alongside Regeneron Pharmaceuticals's historical trend and sector peers before judging valuation or financial health.

Over the past year, 0R2M.L's EBIT moved from $4B to $4.5B — a 10.9% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Regeneron Pharmaceuticals's operating scale or balance-sheet position.

Against Healthcare companies, 0R2M.L currently prints $4.5B for EBIT, while the sector average sits near $1.9T. That is roughly 99.8% below the sector mean. Large gaps often invite a closer look at Regeneron Pharmaceuticals's growth, margins, and balance sheet.

A EBIT figure of $4.5B for 0R2M.L is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $1.9T. Explore the charts below for those layers of context.

After noting 0R2M.L's EBIT ($4.5B), review year-over-year change from $4B, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.